Prothena Corporation plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gene G. Kinney
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 77 Sir John Rogerson’s Quay Dublin United States of America 2
- IPO Date
- Dec 18, 2012
- CIK
- 0001559053
- Website
- prothena.com
- Similar Companies
- Business
- Prothena Corporation plc, a clinical-stage biotechnology company focused on the discovery and development of novel investigational therapies targeting protein dysregulation in neurodegenerative and rare peripheral amyloid diseases, advances a pipeline including PRX012, an anti-amyloid beta monoclonal antibody in Phase 1 for early Alzheimer's disease with data expected in 2025; prasinezumab, a humanized monoclonal antibody targeting alpha-synuclein in Phase 2b for Parkinson's disease and other synucleinopathies; coramitug for transthyretin amyloidosis (ATTR-CM); BMS-986446 and PRX019 targeting tau and TDP-43 respectively in collaboration with Bristol Myers Squibb; and PRX123, a preclinical dual amyloid beta-tau vaccine. The company, founded in 2012 through a spin-off from Elan Corporation plc and headquartered in Dublin, Ireland, with research operations in South San Francisco, California, serves patient populations affected by devastating conditions such as Alzheimer's disease, Parkinson's disease, ALS, and ATTR amyloidosis primarily in the United States and globally through partnerships. Recent developments include the discontinuation of the birtamimab program for AL amyloidosis following the Phase 3 AFFIRM-AL trial failure, a shift emphasizing PRX012 as the lead wholly-owned asset with higher-dose subcutaneous formulations advancing toward topline results in August 2025; progression of partnered programs with Roche on prasinezumab potentially entering Phase 3 by year-end 2025, Novo Nordisk's Phase 2 data for coramitug in the second half of 2025, and Bristol Myers Squibb's ongoing tau and TDP-43 efforts; and initiation of a Phase 1 trial for PRX019 in Q3 2025 alongside a poster presentation on its TDP-43 program at Neuroscience 2025.
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Announces Leadership Team Updates
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy
89,704 Shares in Prothena Corporation plc $PRTA Acquired by Assenagon Asset Management S.A.
Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA